Inhibitex, Inc. (Nasdaq: INHX) announced today that the Company was added to the broad-market Russell 3000® Index, as well as its Microcap and Global Indexes, when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on Friday June 25, 2010.

Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000® also provides for automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.9 trillion in assets are currently benchmarked to these indexes.

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing innovative products to prevent and treat serious infectious diseases. The Company’s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles; INX-189, a nucleotide polymerase inhibitor in Phase I clinical development for the treatment of chronic hepatitis C infections; and a staphylococcal vaccine based on its proprietary MSCRAMM protein platform that is partnered with Pfizer and currently in Phase I clinical development.

For additional information about the Company, please visit www.inhibitex.com.

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.